Intelligent Bio Solutions Inc. (Nasdaq: INBS) announced financial results for the fiscal fourth quarter and full year ended June 30, 2025.
The company showcased progress on planned U.S. market expansion, revenue growth, and operational efficiencies.
Revenue growth of 16% in the fourth quarter was driven by increased demand for drug testing cartridges.
Progress Toward FDA Clearance
INBS focused on securing FDA 510(k) clearance for its opiate test system for codeine in the U.S., advancing regulatory strategy through enhanced clinical study design and new data generation.
Expansion Across Key Markets
Revenue from sales of goods increased by 16% year-on-year, driven by growth in cartridge sales and steady account acquisitions in safety-critical sectors.
Operational Efficiencies and Business Localization
The company implemented measures to improve operational efficiency and strengthen business fundamentals, aiming to support future growth and expansion.
- The company's revenue in the fiscal fourth quarter reached $843,884, reflecting a 16% increase year-on-year and quarter-on-quarter.
- Cartridge sales contributed significantly to revenue growth, with a 9% increase quarter-on-quarter and a 24% increase year-on-year for the fiscal fourth quarter.
Intelligent Bio Solutions Inc. demonstrated strong performance in fiscal 2025, highlighted by revenue growth, strategic market expansion efforts, and operational enhancements. The company's focus on gaining FDA clearance and expanding in key markets positions it for continued success in the future.